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Ipsilateral Recurrence of Nonarteritic Anterior Ischemic Optic 
Neuropathy: A Case Report
Abstract
Nonarteritic anterior ischemic optic neuropathy (NA-AION) is a multifac-
torial disease that is the most common type of ischemic optic neuropathy. 
NA-AION develops in one eye and can later develop in the fellow eye. The 
ipsilateral recurrence of NA-AION is rare and multiple theories have been 
proposed to explain it. This case report describes a patient with unilateral 
recurrence of NA-AION, explores the proposed etiologies, and emphasizes 
visual symptoms following its resolution.
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INTRODUCTION
Nonarteritic anterior ischemic optic neuropathy (NA-AION) represents 
95% of all anterior ischemic optic neuropathies.1 It is one of the most visu-
ally debilitating diseases in patients over the age of 50, with an estimated 
annual incidence in the United States of 2.3 to 10.2 per 100,000 population, 
which equates to approximately 6,000 new cases annually.1 NA-AION af-
fects a significantly higher proportion of Caucasians compared to other rac-
es, with a mean age of onset of 66 years.1 Visual acuity at initial presentation 
is variable; 49% of patients have an initial visual acuity of ≥20/64, while 23% 
to 34% have an initial visual acuity of ≤20/200.1,2 Further, 38% have minimal 
to mild visual field defects and 43% have marked to severe defects.2 
The pathogenesis of NA-AION, albeit controversial, has been proposed to 
involve one of two mechanisms. The most commonly accepted mechanism 
is transient nonperfusion or hypoperfusion of the optic nerve head (ONH).3 
The second proposed cause is embolic occlusion of the arterioles supplying 
the ONH.3 When considering the former, two main categories of risk fac-
tors exist: predisposing risk factors (differentiated into systemic risk fac-
tors and local ONH risk factors) and precipitating risk factors.4 
The occurrence of NA-AION in the contralateral eye is possible, and ap-
proximately 25% of patients suffer involvement in the fellow eye within 3 
years of that in the primary eye.5 However, recurrence in the same eye is rare. 
In a study including 594 consecutive patients with NA-AION, only 6% de-
veloped NA-AION a second time in the ipsilateral eye.6 The following case 
report highlights an ipsilateral recurrence of NA-AION and expands on the 
proposed etiologies of NA-AION, with an emphasis on ipsilateral recurrence. 
Additionally, common visual complaints in NA-AION are discussed. 
CASE REPORT
In 2017, a 76-year-old Caucasian man presented to our clinic with com-
plaints of new-onset intermittent brown spots of different shapes and sizes 
in the central vision of his right eye. These spots began three days prior and 
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were noted a few times per day. He additionally described a “glow” on the right side of his vision with an associated 
dull ache behind his right eye. He denied headache, scalp tenderness, jaw claudication, fever, weight loss, Uhthoff”s 
phenomenon, numbness, and weakness. 
His medical history was notable for hypertension, hyperlipidemia, coronary artery disease, venous insufficiency, 
gastroesophageal reflux, insomnia, and left-sided Bell’s Palsy 20 years previously. Current medications were citalo-
pram (Celexa), furosemide (Lasix), lisinopril (Zestril), metoprolol (Lopressor), nitroglycerin (Nitrostat), omepra-
zole (Prilosec), simvastatin (Zocor), and 325mg aspirin (Bayer). He denied use of phosphodiesterase-5 inhibitors, 
tobacco, alcohol, or recreational drugs. 
His past ocular history was significant for NA-AION OS in 2007 and visually insignificant cataracts OU. He denied 
any history of eye surgeries, eye trauma, or family history of ocular disease. 
His blood pressure was 142/79 mm Hg at 2:30pm. 
His best-corrected visual acuity was 20/20-1 OD and finger-counting at 0.3 meters OS. He had normal ocular mo-
tility without pain or double vision. Pupils were equal and round with a 3+ left relative afferent pupillary defect. 
Confrontation visual fields revealed an inferior nasal restriction OD and complete inferior restriction OS. Color vi-
sion testing with HRR pseudoisochromatic plates was intact OD (6/6 plates) and could not be performed OS due to 
his profoundly reduced acuity. The right and left superficial temporal arteries were easily palpable and nontender. 
Slit-lamp biomicroscopy was unremarkable, with the exception of 2+ nuclear sclerotic cataracts OU. Intraocular 
pressures were 15 mm Hg OU at 2:00pm as measured with Goldmann applanation tonometry. 
Dilated fundus examination showed superior ONH edema OD with a solitary albeit large retinal nerve fiber layer 
hemorrhage at the nasal margin (Figure 1). The left ONH had diffuse pallor with distinct margins (Figure 2). For 
reference, the cup to disc ratios were previously determined to be 0.3 round OD and 0.25 round OS with an optic 
disc size of 1.6mm OU. The remainder of the fundus examination was unremarkable. 
Additional testing was pursued including spectral domain optical coherence tomography (SD-OCT) imaging of the 
peripapillary retinal nerve fiber layer (pRNFL) (Figure 3). This was obtained with a Heidelberg Spectralis SD-OCT 
(Heidelberg Engineering, Inc., Heidelberg, Germany) and revealed hemispheric superior pRNFL edema with nor-
mal inferior pRNFL thickness. 
Figure 1: Fundus photograph taken at the initial visit OD. Superior ONH edema with a nasal flame shaped hemorrhage is evident.
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Figure 2: Fundus photograph OS showing diffused ONH pallor.
Figure 3: OCT-RNFL OD acquired at the initial visit shows hemispheric superior thickening.
Differential diagnoses considered for this patient included other potential causes of ONH edema, as well as possible 
causes of ONH edema in one eye and ONH pallor in the fellow eye. These included demyelinating (multiple scle-
rosis), inflammatory (sarcoidosis, systemic lupus erythematosus), compressive (optic nerve sheath meningioma, 
Foster Kennedy syndrome), infectious (tuberculosis, bartonella, syphilis, Lyme), neoplastic (lymphoma, leukemia, 
glioma), and vascular (arteritic anterior ischemic optic neuropathy (A-AION), NA-AION) etiologies.7
Despite the presumptive diagnosis of NA-AION, same-day lab-testing was pursued and included a comprehensive 
metabolic panel (CMP), complete blood count (CBC), C-reactive protein (CRP), erythrocyte sedimentation rate 
(ESR), and glycated hemoglobin (HBA1c). All the results were within normal reference ranges for the patient’s age 
and existing comorbidities: specifically, an ESR of 7 mm/h and a CRP of <5.0 mg/L helped rule out A-AION second-
ary to giant cell arteritis. A previous sleep study showed no sleep apnea.
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Due to the clinical presentation and normal lab-testing results, a diagnosis of NA-AION was made. The patient was 
educated on the findings and the course of the disease, and on better control of potential risks factors for NA-AION, 
including his underlying systemic diseases. Additionally, the timing of the use of his systemic anti-hypertensive 
medications was discussed in detail. The patient denied use of his systemic anti-hypertensive medications within 
3 to 4 hours of falling asleep despite altered sleeping patterns due to insomnia. A note was sent to his primary care 
provider with today’s exam findings. The patient was directed to return to the clinic in one week for ongoing care, 
including dilated fundus exam, SD-OCT, and Humphrey visual field 24-2 testing (HVF 24-2).
The patient presented one week later with no new visual or systemic complaints. His best-corrected visual acuity 
was 20/20-2 OD and finger-counting at 0.3 meters OS. The remaining preliminary tests were stable and consistent 
with the previous visit. Dilated fundus examination displayed a similar ONH appearance OD (Figure 4), although 
SD-OCT revealed a slight decrease in the superior pRNFL thickness consistent with resolving edema OD (Figure 5). 
HVF 24-2 testing could not be performed at this visit due to malfunctioning equipment. The patient was educated 
on the course of NA-AION and directed to return in one month for HVF 24-2 testing. 
Figure 4: Fundus photograph OD one week after initial presentation.
Figure 5: OCT-RNFL OD acquired one week after initial presentation shows improvement in hemispheric superior thickening 
with mild thickening nasal.
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At the 10th week follow-up visit (the patient missed his fifth week follow-up), the patient had new complaints of reduced 
central visual acuity in his right eye of three days’ duration. Additionally, he now noticed changes in his ability to distin-
guish shades and had an increase in light sensitivity. His best corrected visual acuity was reduced to 20/30- OD. Mars 
Letter Contrast Sensitivity testing of the right eye showed a severe contrast sensitivity loss, with a log value of 0.56. 
Dilated fundus examination demonstrated near-complete resolution of the superior ONH edema and RNFL hemor-
rhage, however inferior ONH edema was now present (Figure 6). SD-OCT confirmed this presentation with thinning 
of the pRNFL in the superior temporal sector and thickening in the inferior hemisphere (Figure 7). An HVF 24-2 test 
using a SITA Standard strategy OD was reliable with fixation losses of 1/18, false-positive errors of 0%, false-negative 
errors of 20%, and excellent gaze-tracking. The mean deviation was -16.50dB and the visual field index was 46%. 
There were dense inferior and superior central defects consistent with both previous superior and current inferior 
ONH involvement, respectively (Figure 8). HVF 24-2 testing was not attempted OS due to profound vision loss.
Figure 6: Fundus photograph OD taken six weeks after initial presentation now shows inferior ONH edema.
Figure 7: OCT-RNFL OD acquired six weeks after initial presentation shows complete resolution of hemispheric superior 
thickening, superior temporal sector thinning, and new hemispheric inferior thickening.
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Figure 8: Humphrey visual field 24-2 sita standard testing following the initial and recurrent NA-AION OD.
The patient was educated on the rarity of his ipsilateral recurrence of NA-AION. The importance of controlling po-
tential systemic risk factors was reinforced, resulting in the patient admitting to poor adherence with his prescribed 
medications. Further, he noted that his sleep schedule had changed over the last few weeks secondary to stress and 
he had begun to use his systemic anti-hypertensive medications closer to falling asleep. 
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The patient was scheduled to return in one month for a dilated fundus examination with SD-OCT testing OD and to 
repeat the HVF 24-2 OD. He was also referred for vision rehabilitation services to help improve his daily activities 
that had become affected. 
One month later (14th week follow-up) there was complete resolution of the ONH edema. The disc was now diffuse-
ly pale secondary to the post edema atrophic process (Figure 9). The visual field defect and visual acuity remained 
unchanged. The patient was to keep his scheduled vision rehabilitation evaluation and return in four months for 
HVF 10-2 testing. The patient did not return for follow-up examinations beyond his visual rehabilitation care.
Figure 9: Fundus photograph OD taken ten weeks after initial presentation and four weeks after the ipsilateral recurrence 
shows reduced inferior ONH edema and increased ONH pallor.
During the visual rehabilitation exam our patient demonstrated a difficulty with contrast sensitivity and photopho-
bia that we were able to improve with the use of a light-amber filter for inside wear and a wraparound dark-amber 
filter for outside wear. The patient was also provided a handheld video magnifier with built-in contrast enhance-
ment to facilitate reading tasks. A discussion of driving restrictions was not required as the patient ceased driving 
on his own accord following his first NA-AION occurrence.
DISCUSSION
Non-arteritic anterior ischemic optic neuropathy (NA-AION) is an ischemic disorder of the posterior ciliary artery 
(PCA) circulation, the main source of blood supply to the optic nerve head (ONH).8-10 More recent studies using optical 
coherence tomography angiography (OCT-A) have shown impaired flow in both the retinal peripapillary capillaries 
(RPC) and peripapillary choriocapillaris (PCC) following an episode of NA-AION.11,12 These areas show a strong cor-
respondence to both functional and structural changes.11 Presumably, hypoperfusion of the RPC after an episode of 
NA-AION results as a consequence of an inciting ischemic event within the PCA circulation.11 One proposed explana-
tion for this decrease in RPC perfusion is that RPCs possess unique anatomical features not found in other capillaries: 
they tend to be longer and straighter, and connect large-caliper arteries to the long venous trunk directly, without 
anastomosis.12 These peculiarities make RPCs more sensitive to changes in blood flow, such as those that occur with 
ischemic events within the PCA circulation.12
The exact pathogenesis of NA-AION remains controversial, but has been proposed to involve one of two processes. 
Most commonly, transient non-perfusion or hypoperfusion of the ONH is cited. Rarely, NA-AION is attributed to 
embolic lesions of the arterioles supplying the ONH.8 The former will be discussed below. 
Fluorescein angiography (FA) at the onset of NA-AION has shown delayed filling of the peripapillary choroid and its 
watershed zones (a border between the territories of distribution of any two end arteries) as opposed to a complete lack 
of filling.13 This can be interpreted to mean that these vessels are not absolutely occluded.13 Since there is only a transient 
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loss of circulation to the ONH, there is usually a much less severe ischemic cascade and resultant ONH damage. This 
was demonstrated in two large studies, in which approximately 41% of eyes with NA-AION showed spontaneous visual 
improvement.1,2 It is postulated that this hypoperfusion is a result of the drop in perfusion pressure of the capillaries of 
the ONH below the critical autoregulatory range.8 Autoregulation is critical in maintaining proper blood flow to a tissue 
through the dilatation and constriction of blood vessels in response to perfusion pressure and local metabolic demand. 
However, autoregulation will only operate over a certain range of perfusion pressure and becomes ineffective beyond that 
range; at this point, blood flow to the ONH becomes directly correlated to the perfusion pressure.14 
Several variables, in different combinations, can render the ONH more susceptible to an ischemic insult. The spe-
cific combination of factors that result in NA-AION will be unique to each patient affected, underscoring the notion 
that NA-AION is multifactorial in nature.8 These risk factors can be categorized as either predisposing risk factors 
(differentiated into systemic risk factors and local ONH risk factors) or precipitating risk factors.4
Predisposing risk factors make the ONH more susceptible to an ischemic event. Systemic factors include arterial hy-
pertension, diabetes mellitus, ischemic heart disease, sleep apnea, and hyperlipidemia, among others.15-17 Several of 
these risks factors were present in our patient. Local ONH factors may also play a predisposing role, and include ab-
sent or small cup in the optic disk (secondary contributing factor),18 significantly raised IOP,19 optic disk drusen,19 and 
the location of the watershed zone formed by the distribution of the posterior ciliary arteries in relation to the ONH.20 
The most notable precipitating risk factor that may ultimately act as the final insult to the susceptible nerve, leading to 
the cascade of ischemia that deprives the ONH, is nocturnal arterial hypotension.21-23 It has been documented that 73% of 
patients with NA-AION specifically reported that their vision loss was noted upon waking from sleep/nap or when they 
first used their vision critically.24 Furthermore, 24-hour ambulatory blood pressure monitoring has shown many cases of 
nocturnal arterial hypotension in individuals who developed NA-AION.22,23 A significant relationship between nocturnal 
arterial hypotension and the use of potent oral anti-hypertensive therapy has been established.22,23 In fact, since the ad-
vent of these hypotensive treatment agents, there has been a rise in the incidence of NA-AION.8 In this case, the patient 
was taking three potent hypotensive drugs, and admittedly dosed them near bedtime prior to the ipsilateral recurrence. 
For patients with NA-AION, the risk of contralateral eye involvement is reported to range from 14.7% to 25% over 
three to five years.5,25 However, recurrence in the ipsilateral eye is considered to be rare. It is important to differenti-
ate true ipsilateral recurrence from a progression of NA-AION during the acute stage of the disease. 
Optic nerve edema has a characteristic evolutionary pattern in NA-AION.26 Initially, a portion of the ONH is edematous, 
with the remainder of the disc unaffected. After several days, the entire nerve can manifest diffusely generalized edema. 
Sequentially, the initially involved section of the ONH will develop pallor in response to the previous ischemic axonal 
insult. Edema may persist throughout the rest of the ONH. This edema will also gradually resolve, with resultant pallor. 
In this case, from initial presentation to one week post presentation, there was some resolution of the superior 
edema with a subtle increase in the inferior nasal edema (Figure 3 and Figure 5). This migration of edema from its 
starting point to an originally uninvolved area is not uncommon based on the findings described previously. From 
one week through 10 weeks post presentation, the superior edema fully resolved, leaving some RNFL thinning. 
However, significant inferior edema, well beyond what was seen with the initial migration of edema at the one week 
post presentation, had developed (Figure 5 and Figure 7). This new development of significant inferior ONH edema, 
coupled with the 7.9 week median average time for complete resolution of ONH edema after acute NA-AION26 sub-
stantiate that the patient suffered from recurrent ipsilateral NA-AION. 
Several hypotheses have been suggested to explain the rarity of ipsilateral recurrence of NA-AION, including the 
inability of the patient to recognize further visual loss after the initial episode,27 shunting of blood from the damaged 
to the healthy part of the ONH,27 and initial destruction of the RNFL in a crowded optic disk providing more space 
for the surviving RNFL28. However, these postulated ideas have been largely discredited, and in most recurrent epi-
sodes of NA-AION, the cause remains unidentified.6 
In most cases of primary NA-AION, a single definitive cause cannot be identified. Despite this fact, it is incumbent 
upon eye-care providers, in concert with other members of the patient’s healthcare team, to detect predisposing 
and precipitating risk factors, some of which may be mitigated. By doing so, ocular morbidity can be minimized by 
lowering the chance of contralateral eye involvement and ipsilateral recurrence. Additionally, better management 
of underlying systemic disease can diminish the risk of systemic mortality. 
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In this case, the main focus of care following the patient’s NA-AION was discussing and altering any potential pre-
disposing and precipitating systemic risk factors. However, there is some controversy surrounding the treatment of 
NA-AION with systemic corticosteroids. A large, prospective study of 696 eyes found that, in eyes with initial visual 
acuity of 20/70 or worse, seen within 2 weeks of onset, visual acuity improved in 70% of the treated group compared 
to 41% of the untreated group.29 Others refute the validity of this study, citing several inconsistencies.30 The present-
ing visual acuity in the right eye in this case does not fall within the criteria of the aforementioned study, and thus 
systemic corticosteroids were not considered. 
Visual acuity and visual field loss are common consequences of NA-AION, but are not the only symptoms that pa-
tients struggle with following ischemic damage to the ONH. Contrast sensitivity loss and photophobia are debilitat-
ing problems following NA-AION that can be just as impactful as loss of visual acuity. The world is composed of 
infinite shades, and poor contrast sensitivity prevents patients from deciphering these subtle changes in their visual 
world. Patients will often complain that there is not enough or too much light in the environment, which can cause 
problems with glow and contour detection of objects.31 Additionally, an association between contrast sensitivity and 
functional independence has been shown.31,32 Thus, it is important for vision rehabilitation specialists to address 
four main visual symptoms after NA-AION, including visual acuity, contrast, photophobia, and visual field loss. l
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